Core Insights - OSR Holdings, Inc. provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund, emphasizing that future issuances are not purely dilutive and will support business development [1][3]. Financing and Share Issuance - The company has issued a total of 2,308,382 shares under structured financing, with less than 10% of registered shares utilized under the ELOC agreement [7]. - The registered share capacity under the ELOC agreement is 9,500,000, with 767,500 shares issued since June 17, 2025 [7]. Business Development and Partnerships - Proceeds from financing are being invested in drug R&D, medical device initiatives, and digital asset ecosystems, with a focus on protecting shareholder value [3]. - The Woori IO clinical trial in Korea is being conducted in partnership with a major technology company in mobile and wearable devices, with further details expected after the Stock Purchase Agreement is signed [4]. Company Overview - OSR Holdings, Inc. is dedicated to advancing biomedical innovation in health and wellness, focusing on immuno-oncology, regenerative biologics, and medical device distribution [5]. - The company aims to improve patient care through cutting-edge research and development [5]. Strategic Initiatives - The company is pursuing a "Plug-and-Play" bacterial vector platform for cancer immunotherapy and a Disease-Modifying Osteoarthritis Drug (DMOAD) candidate [8]. - A strategic move is underway to acquire noninvasive glucose monitoring technology through a signed term sheet with Woori IO [8].

Core Viewpoint - Scienture Holdings, Inc. has successfully completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of its FDA-approved product, Arbli, while temporarily suspending further draws until certain conditions are met [1][2][3]. Financial Strategy - The draw on the ELOC is aimed at providing immediate capital for pre-launch activities of Arbli, the first FDA-approved ready-to-use oral liquid losartan in the U.S. market [2]. - The company has decided to pause further ELOC draws for 30 trading days or until its stock price reaches $10 per share, indicating confidence in its business prospects [3]. Product Information - Arbli is a novel antihypertensive medication indicated for treating hypertension in patients over 6 years old, reducing stroke risk in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients [4]. - The product is available in a 165 mL peppermint-flavored suspension that does not require refrigeration and has an 18-month shelf life when stored at room temperature [5]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing enhanced value to patients and healthcare systems by developing and distributing specialty pharmaceutical products [6]. - The company is committed to addressing unmet market needs and has a team of experienced professionals dedicated to bringing unique specialty products to market [6].